CEL-SCI Corporation (CVM) Company Overview

What does CEL-SCI Corporation do?

CEL-SCI Corporation is a late clinical-stage biotechnology company listed on the NYSE American under ticker CVM. Its central project is Multikine, an investigational immunotherapy intended to be administered immediately after diagnosis and before surgery, radiation, or chemotherapy for selected patients with locally advanced squamous cell carcinoma of the head and neck. The company also owns the earlier-stage LEAPS peptide-immunotherapy platform, but its resources and strategic attention are overwhelmingly concentrated on Multikine. The latest Form 10-Q for the quarter ended March 31, 2026 reports one operating segment and no revenue.

Which assets define the company?

Multikine is a patented mixture of 14 naturally derived human cytokines. CEL-SCI’s thesis is that immune stimulation may be more effective before conventional treatment weakens the immune system. The first proposed indication is neoadjuvant treatment in newly diagnosed, previously untreated, resectable head and neck cancer. CEL-SCI’s official Multikine overview describes the therapy as investigational; it has not been approved for sale by the FDA or any other regulator.

How does CEL-SCI make money?

It does not yet generate product revenue. CEL-SCI’s present economic model is to raise capital, fund clinical development and manufacturing readiness, obtain regulatory approval, and then monetize Multikine through product sales, licensing, regional partnerships, or a combination of those routes. The company’s filing states that significant revenue is not expected until it enters licensing arrangements or receives approval to sell its products. Therefore, “how CEL-SCI makes money” is currently a financing-and-optionality question rather than a revenue-mix question.

What would become the principal revenue stream?

If approved, Multikine would be the core product and likely the overwhelming source of initial revenue. The addressable population disclosed by management has narrowed over time: the company previously discussed at least 210,000 patients annually for a broader surgery-plus-radiation population, while the confirmatory study targets approximately 100,000 patients worldwide per year with no clinical lymph-node involvement and low or zero PD-L1 expression. The narrower target improves trial precision but reduces the immediately addressable population. LEAPS remains an option on future development rather than a visible near-term revenue engine.

Why is Multikine scientifically and strategically different?

The key differentiation is timing. Checkpoint inhibitors are generally used after surgery, in unresectable disease, or after other treatment, whereas Multikine is designed for a three-week course before standard care. CEL-SCI argues that an intact immune system is more capable of mounting an anti-tumor response. Its completed study enrolled 928 patients across multiple countries and regulatory jurisdictions, making the clinical dataset unusually large for a small biotechnology company. The company’s Phase 3 trial-design page notes that 24 regulatory agencies authorized the global study.

What did the target-population data show?

In the retrospective target cohort, five-year overall survival was 73% with Multikine plus standard care versus 45% with standard care alone. CEL-SCI reported a hazard ratio near 0.35, with the upper 95% confidence bound at 0.66. Its July 13, 2026 launch announcement described approximately 97% power to test a previously observed 0.34 hazard ratio, plus a 13% objective response rate versus 0% and 35% downstaging versus 13%. The decisive test is prospective replication in 212 patients.

How is the confirmatory study designed?

The planned study is randomized and controlled, comparing Multikine plus standard of care with standard of care alone. Eligibility focuses on newly diagnosed, previously untreated, resectable, locally advanced disease, no clinical lymph-node involvement, and low or zero PD-L1 expression. CEL-SCI announced on July 13, 2026 that it was launching the global study, with enrollment expected across the United States, Europe, Asia, and later South America; that milestone appears on the company’s official news page.

Which turning points still shape CEL-SCI today?

CEL-SCI’s history explains both its unusual asset base and its high-risk capital structure. The company was founded around the idea of cytokine-based cancer immunotherapy long before modern checkpoint inhibitors validated immuno-oncology. It preserved control of Multikine, invested heavily in proprietary manufacturing, and endured repeated financing and operational delays. The official company history shows how persistence created a large clinical dataset, but also why accumulated losses and dilution are so substantial.

1. 1978–1983
   Early research was funded at the Max Planck Institute, and CEL-SCI was founded in 1983 around Multikine. Today’s company remains a single-asset-heavy expression of that original thesis.
2. 1993
   Technology became available to manufacture Multikine at a scale suitable for broad human studies. CEL-SCI committed to commercial development and began building internal manufacturing capabilities.
3. 2001–2008
   Manufacturing validation was completed, orphan-drug designation arrived in 2007, and CEL-SCI took possession of a 73,000-square-foot manufacturing facility in 2008.
4. 2010–2016
   The global Phase 3 study began after facility validation and reached full enrollment of 928 patients in September 2016, several years later than originally planned.
5. 2018
   An arbitrator ruled that the prior CRO materially breached its contract. The episode reinforces the execution risk that comes from outsourcing large clinical programs.
6. 2020–2021
   The study reached its primary endpoint in April 2020, locked the database in December 2020, and reported top-line data in June 2021. Benefit appeared concentrated in the surgery-plus-radiation population.
7. 2024–2026
   The FDA permitted a focused 212-patient confirmatory study; CEL-SCI raised additional equity in May and June 2026 and announced the global study launch on July 13, 2026.

What is the strategic trade-off created by this history?

CEL-SCI owns purpose-built manufacturing and retains control of Multikine, which could preserve economics after approval. Shareholders, however, have financed decades without commercial revenue. The company says more than $200 million was spent developing and validating manufacturing, while the fiscal 2025 accumulated deficit reached $539.4 million. Persistence created a mature asset but also repeated dilution.

What do CEL-SCI’s latest results show?

For the quarter ended March 31, 2026, CEL-SCI remained pre-revenue. Net loss narrowed to $5.47 million from $6.57 million a year earlier. R&D was $3.77 million, down 6%, and G&A was $1.56 million, down about 34%. Cost reductions—not product revenue—drove the improvement.

How did the first half of fiscal 2026 compare?

For the six months ended March 31, 2026, operating expenses fell to $10.69 million from $13.29 million. R&D declined 12% to $7.44 million, G&A declined 33% to $3.25 million, and net loss narrowed to $10.94 million from $13.65 million. Operating cash use was $8.04 million versus $8.51 million; with no capex, free-cash-flow burn was essentially identical.

How financially strong is CEL-SCI?

Liquidity is CEL-SCI’s central constraint. At March 31, 2026, cash was $1.89 million, current assets $2.89 million, and current liabilities $4.81 million. Total assets were $17.71 million, liabilities $10.83 million, and equity $6.87 million. The filing raised substantial doubt about continued operation because of recurring losses and limited cash.

What changed after the quarter?

CEL-SCI sold 6.0 million shares at $1.20 in May 2026 for $7.2 million gross and about $6.5 million net, then 2.5 million shares at $1.00 in June for $2.5 million gross and an estimated $2.2 million net. Pro forma net tangible book value was about $15.5 million, or $0.93 per share. The raises improved liquidity but did not fully fund the estimated $30 million–$35 million trial.

What gives CEL-SCI a competitive advantage?

CEL-SCI does not possess a conventional commercial moat because it has no approved product, sales force, reimbursement history, or recurring revenue. Its potential advantage is an integrated package: a differentiated pre-surgical mechanism, a large completed randomized dataset, orphan-drug designation, intellectual property, and a dedicated manufacturing facility. The company’s business-strategy page emphasizes first-line immune activation and the attempt to serve patients whose tumors have low PD-L1 expression.

Which resources could be difficult to replicate?

The strongest resource is the combination of manufacturing know-how, regulatory history, and patient-level evidence. CEL-SCI says it spent more than $200 million validating Multikine manufacturing and operates a 73,000-square-foot facility near Baltimore. Replicating the biologic and its clinical package would be difficult, but those resources create value only if the confirmatory study succeeds.

Who are the real competitors?

Competitors include existing surgery, radiation, chemoradiotherapy, checkpoint inhibitors such as pembrolizumab and nivolumab, and other neoadjuvant trials. Multikine is intended to complement standard care in low-PD-L1, node-negative patients. Adoption would still depend on survival evidence, safety, reimbursement, workflow burden, and competing pre-surgical regimens.

Who owns CEL-SCI stock, and why does governance matter?

CEL-SCI has one common share class with one vote per share, so it is not founder-controlled through a dual-class structure. The 2026 proxy reported 17.48 million common shares outstanding as of June 18, 2026, after the May and June financings. Chief Executive Officer Geert Kersten beneficially owned 642,018 shares, or 3.6%, while all six officers and directors as a group beneficially owned 821,986 shares, or 4.63%. The latest 2026 definitive proxy statement did not list any outside 5% holder in its principal-shareholder table.

What does the ownership structure signal?

Ownership is dispersed; management influence comes from tenure and board roles, not majority voting control. Kersten has led CEL-SCI since 1995 and has been involved since 1987. Two independent directors serve across the audit, compensation, and governance committees, supporting continuity but concentrating oversight.

What opportunities and risks could change the outlook?

Prospective replication could support regulatory submissions, validate a new treatment sequence, and attract larger oncology partners. Failure, slow enrollment, added regulatory demands, manufacturing problems, or unfavorable financing could instead impair the asset and dilute shareholders.

Which risk is most material?

Clinical reproducibility is the primary risk because the confirmatory population came from a subgroup analysis. Regulators will focus on whether prospectively defined eligibility, execution, and endpoints reproduce the effect. CEL-SCI’s fiscal 2025 Form 10-K also details financing, CRO, manufacturing, intellectual-property, cybersecurity, and going-concern risks.

Which KPIs matter most for CEL-SCI valuation?

A conventional DCF is fragile because CEL-SCI has no approved product, revenue base, observable gross margin, or reliable launch date. A risk-adjusted model should emphasize probability of approval, time to market, eligible patients, penetration, net price, margins, partner economics, and dilution. Clinical probability and timing matter more than small discount-rate changes.

How should a DCF or rNPV be structured?

Start with the approximately 100,000-patient annual target cohort, then apply launch timing, approval probability, penetration, price, net-to-gross deductions, and partner economics. Deduct commercial, manufacturing, tax, and working-capital needs; add cash and subtract obligations. Divide by a forward fully diluted share count reflecting the post-quarter offerings and likely future financing, not only the March 31, 2026 base.

What is the key takeaway from CEL-SCI analysis?

CEL-SCI is a concentrated clinical and financing case, not a normal operating company. Its importance lies in immune stimulation before standard treatment and decades of Multikine clinical and manufacturing work. The historical target-cohort result justifies a focused confirmatory study, and the July 2026 launch was a meaningful step.

The concentration also creates exceptional risk: no revenue, a going-concern disclosure, accumulated losses, and a study budget far above March 2026 cash. May and June financings improved liquidity, while offerings and related issuances lifted shares outstanding to 17.48 million by June 18. CEL-SCI must still fund enrollment, reproduce survival results, satisfy regulators, validate manufacturing, and establish commercialization.